JP2024112876A5 - - Google Patents

Download PDF

Info

Publication number
JP2024112876A5
JP2024112876A5 JP2024079088A JP2024079088A JP2024112876A5 JP 2024112876 A5 JP2024112876 A5 JP 2024112876A5 JP 2024079088 A JP2024079088 A JP 2024079088A JP 2024079088 A JP2024079088 A JP 2024079088A JP 2024112876 A5 JP2024112876 A5 JP 2024112876A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
human subject
composition according
human
recombinant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024079088A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024112876A (ja
Filing date
Publication date
Priority claimed from JP2019541264A external-priority patent/JP2020508289A/ja
Application filed filed Critical
Publication of JP2024112876A publication Critical patent/JP2024112876A/ja
Publication of JP2024112876A5 publication Critical patent/JP2024112876A5/ja
Pending legal-status Critical Current

Links

JP2024079088A 2017-01-31 2024-05-15 完全ヒトグリコシル化ヒトα-L-イズロニダーゼ(IDUA)を用いたムコ多糖症I型の治療 Pending JP2024112876A (ja)

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US201762452769P 2017-01-31 2017-01-31
US62/452,769 2017-01-31
US201762485655P 2017-04-14 2017-04-14
US62/485,655 2017-04-14
US201762529366P 2017-07-06 2017-07-06
US62/529,366 2017-07-06
US201762579690P 2017-10-31 2017-10-31
US62/579,690 2017-10-31
US201862616234P 2018-01-11 2018-01-11
US62/616,234 2018-01-11
JP2019541264A JP2020508289A (ja) 2017-01-31 2018-01-30 完全ヒトグリコシル化ヒトα−L−イズロニダーゼ(IDUA)を用いたムコ多糖症I型の治療
PCT/US2018/015910 WO2018144441A1 (en) 2017-01-31 2018-01-30 Treatment of mucopolysaccharidosis i with fully-human glycosylated human alpha-l-iduronidase (idua)

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2019541264A Division JP2020508289A (ja) 2017-01-31 2018-01-30 完全ヒトグリコシル化ヒトα−L−イズロニダーゼ(IDUA)を用いたムコ多糖症I型の治療

Publications (2)

Publication Number Publication Date
JP2024112876A JP2024112876A (ja) 2024-08-21
JP2024112876A5 true JP2024112876A5 (cg-RX-API-DMAC7.html) 2024-11-15

Family

ID=63041038

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019541264A Pending JP2020508289A (ja) 2017-01-31 2018-01-30 完全ヒトグリコシル化ヒトα−L−イズロニダーゼ(IDUA)を用いたムコ多糖症I型の治療
JP2024079088A Pending JP2024112876A (ja) 2017-01-31 2024-05-15 完全ヒトグリコシル化ヒトα-L-イズロニダーゼ(IDUA)を用いたムコ多糖症I型の治療

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2019541264A Pending JP2020508289A (ja) 2017-01-31 2018-01-30 完全ヒトグリコシル化ヒトα−L−イズロニダーゼ(IDUA)を用いたムコ多糖症I型の治療

Country Status (12)

Country Link
US (2) US20190358303A1 (cg-RX-API-DMAC7.html)
EP (1) EP3576768A4 (cg-RX-API-DMAC7.html)
JP (2) JP2020508289A (cg-RX-API-DMAC7.html)
KR (2) KR102761412B1 (cg-RX-API-DMAC7.html)
AU (1) AU2018216807A1 (cg-RX-API-DMAC7.html)
BR (1) BR112019015482A2 (cg-RX-API-DMAC7.html)
CA (1) CA3049915A1 (cg-RX-API-DMAC7.html)
IL (1) IL268076B2 (cg-RX-API-DMAC7.html)
MA (1) MA47436A (cg-RX-API-DMAC7.html)
SG (1) SG11201906452PA (cg-RX-API-DMAC7.html)
UY (1) UY37587A (cg-RX-API-DMAC7.html)
WO (1) WO2018144441A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3068328A1 (en) 2017-07-06 2019-01-10 The Trustees Of The University Of Pennsylvania Aav9-mediated gene therapy for treating mucopolysaccharidosis type i
EP3684938A1 (en) 2017-09-22 2020-07-29 The Trustees of the University of Pennsylvania Gene therapy for treating mucopolysaccharidosis type ii
IL280198B2 (en) * 2018-07-18 2026-01-01 Regenxbio Inc Treatment of mucopolysaccharidosis I with fully glycosylated human iduronidase-alpha-L (idus)
KR20220131522A (ko) * 2020-01-22 2022-09-28 리젠엑스바이오 인크. 완전-인간 글리코실화된 인간 알파-l-이두로니다아제 (idua)를 사용한 점액다당류증 i의 치료
CN116887868A (zh) * 2020-12-07 2023-10-13 太空飞船七有限责任公司 达农病的治疗
MX2023008826A (es) 2021-02-01 2023-09-15 Regenxbio Inc Terapia génica para lipofuscinosis neuronal ceroidea.
AU2022379625A1 (en) * 2021-10-27 2024-05-16 The University Of North Carolina At Chapel Hill Aav-idua vector for treatment of mps i

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5196315A (en) * 1990-05-01 1993-03-23 The Johns Hopkins University Human neuronal cell line
EP0578790A4 (en) * 1991-11-14 1994-11-02 Womens & Childrens Hospital SYNTHETIC ALPHA-L-IDURONIDASE AND THESE ENCODING GENETIC SEQUENCES.
TWI235158B (en) * 1997-09-01 2005-07-01 Kirin Brewery Human thrombopoietin produced by human established cell lines, processes foe preparing the same, and pharmaceutical composition comprising the same
WO1999058691A2 (en) * 1998-05-13 1999-11-18 Harbor-Ucla Recombinant (alpha)-l-iduronidase, methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof
US6596535B1 (en) 1999-08-09 2003-07-22 Targeted Genetics Corporation Metabolically activated recombinant viral vectors and methods for the preparation and use
US6585971B1 (en) * 1999-11-12 2003-07-01 Harbor-Ucla Research And Education Institute Recombinant α-L-iduronidase, methods for producing and purifying the same and methods for treating disease caused by deficiencies thereof
US6426208B1 (en) * 1999-11-12 2002-07-30 Harbor-Ucla Research And Education Institute Recombinant α-L-iduronidase, methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof
AU2001267337A1 (en) * 2000-06-30 2002-01-14 Maxygen Aps Peptide extended glycosylated polypeptides
CN103589692B (zh) 2001-11-13 2018-07-24 宾夕法尼亚大学托管会 检测和/或鉴定腺伴随病毒(aav)序列以及分离所鉴定的新型序列的方法
DK2359869T3 (en) 2001-12-17 2019-04-15 Univ Pennsylvania Sequences of adeno-associated virus (AAV) serotype 8, vectors containing these, and uses thereof
AU2004257367A1 (en) * 2003-07-16 2005-01-27 Resverlogix, Inc. Compounds and methods for downregulating the effects of TGF-beta
EP1668143B1 (en) 2003-09-30 2013-03-20 The Trustees of The University of Pennsylvania Adeno-associated virus (aav) clades, sequences, vectors containing same, and uses therefor
EP1765846A4 (en) * 2004-07-13 2010-02-17 Cell Genesys Inc AAV VECTOR COMPOSITIONS AND ITS USE IN PROCESSES FOR INCREASING IMMUNOGLOBULIN EXPRESSION
DE23193606T1 (de) 2005-04-07 2024-02-15 The Trustees Of The University Of Pennsylvania Verfahren zur erhöhung der funktion eines aav-vektors
JP4495210B2 (ja) 2005-06-09 2010-06-30 パナソニック株式会社 振幅誤差補償装置及び直交度誤差補償装置
US9375440B2 (en) * 2006-11-03 2016-06-28 Medtronic, Inc. Compositions and methods for making therapies delivered by viral vectors reversible for safety and allele-specificity
US8734809B2 (en) 2009-05-28 2014-05-27 University Of Massachusetts AAV's and uses thereof
US8927514B2 (en) 2010-04-30 2015-01-06 City Of Hope Recombinant adeno-associated vectors for targeted treatment
US8628966B2 (en) 2010-04-30 2014-01-14 City Of Hope CD34-derived recombinant adeno-associated vectors for stem cell transduction and systemic therapeutic gene transfer
US10738326B2 (en) 2010-10-27 2020-08-11 Jichi Medical University Adeno-associated virus vector for gene transfer to nervous system cells
CA2826273C (en) 2011-02-10 2021-11-02 The University Of North Carolina At Chapel Hill Viral vectors with modified transduction profiles and methods of making and using the same
DK3693025T3 (da) 2011-04-22 2022-01-10 Univ California Adenoassocierede virus-virioner med variant capsid og fremgangsmåder til anvendelse heraf
EP3795581A3 (en) 2011-08-24 2021-06-09 The Board of Trustees of the Leland Stanford Junior University New avv capsid proteins for nucleic acid transfer
EP3470523A1 (en) 2012-05-09 2019-04-17 Oregon Health & Science University Adeno associated virus plasmids and vectors
EP2970946A4 (en) 2013-03-13 2016-09-07 Philadelphia Children Hospital ADENOASSOZED VIRUS VECTORS AND METHOD FOR USE THEREOF
JP2016523835A (ja) * 2013-05-15 2016-08-12 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 中枢神経系へのアデノ随伴ウイルスを介した遺伝子導入
AU2014310360B2 (en) * 2013-06-11 2019-10-24 PPL (BVI) Limited Structure, manufacturing and uses of human-derived cell-permeable peptides conjugated with specific biologically active cargo peptides
US10906981B2 (en) * 2013-07-19 2021-02-02 The Regents Of The University Of California Compositions and methods related to structures that cross the blood brain barrier
EP3564379A1 (en) 2013-09-13 2019-11-06 California Institute of Technology Selective recovery
HUE052676T2 (hu) 2013-10-11 2021-05-28 Massachusetts Eye & Ear Infirmary Eljárások õsi vírusszekvenciák elõrejelzésére és alkalmazásaik
GB201403684D0 (en) 2014-03-03 2014-04-16 King S College London Vector
US10746742B2 (en) 2014-04-25 2020-08-18 Oregon Health & Science University Methods of viral neutralizing antibody epitope mapping
US10577627B2 (en) 2014-06-09 2020-03-03 Voyager Therapeutics, Inc. Chimeric capsids
CN107148275A (zh) * 2014-10-20 2017-09-08 神经干细胞公司 包含编码生长因子的外源多核苷酸的稳定的神经干细胞及其使用方法
JP2017534640A (ja) * 2014-11-10 2017-11-24 アレクシオン ファーマシューティカルズ, インコーポレイテッド アルファ−l−イズロニダーゼ、イズロン酸−2−スルファターゼおよびアルファガラクトシダーゼaの治療用組成物ならびにそれらの使用方法
WO2016200543A2 (en) * 2015-05-13 2016-12-15 The Trustees Of The University Of Pennsylvania Aav-mediated expression of anti-inluenza antibodies and methods of use thereof

Similar Documents

Publication Publication Date Title
TWI879721B (zh) 用於nt-3基因療法之方法及材料
JP2020079234A (ja) 筋萎縮性側索硬化症および他の脊髄障害のための遺伝子治療
US20230279430A1 (en) Gene therapy for mucopolysaccharidosis iiia
JP7384797B2 (ja) ムコ多糖症iiib型のための遺伝子療法
BRPI0611540A2 (pt) terapia de gene para distúrbios de espinha dorsal
Sawada et al. Neuron-targeted caveolin-1 improves neuromuscular function and extends survival in SOD1G93A mice
JP2024095680A5 (cg-RX-API-DMAC7.html)
EP3292206A1 (en) Glucocerebrosidase gene therapy for parkinson's disease
US20240218394A1 (en) Gene therapy for ocular disorders
Zhao et al. In vivo applications and toxicities of AAV-based gene therapies in rare diseases
Shiozawa et al. Tyrosine triple mutated AAV2-BDNF gene therapy in an inner retinal injury model induced by intravitreal injection of N–methyl-D-aspartate (NMDA)
AU2020369570A1 (en) Compositions for DRG-specific reduction of transgene expression
JP2022525564A (ja) アンジェルマン症候群を治療するためのベクターおよび方法
US20240115735A1 (en) Materials and methods for the treatment of lysosomal acid lipase deficiency (lal-d)
JP2024511024A (ja) 21-ヒドロキシラーゼ欠損症の遺伝子治療
JP7832898B2 (ja) クラッベ病の治療に有用な組成物
US20240189452A1 (en) Recombinant Adeno-Associated Virus Encoding Methyl-CPG Binding Protein 2 for Treating PITT Hopkins Syndrome VIA Intrathecal Delivery
TW202333776A (zh) 用於治療腦白質失養症的方法及組合物
US20160303205A1 (en) Combination Therapies for Lysosomal Storage Diseases
Mcdougald Reprogramming the retina: next generation strategies of retinal neuroprotection and gene therapy vector potency assessment
EA052396B1 (ru) Способы и материалы для направленной на nt-3 генной терапии
Hironaka et al. Noriko Miyake1, Koichi Miyake1, takashi okada1, Akio Morita2 & takashi shimada1